Zhiyi Biotech Raised $45 Million In Series B Funding Round To Accelerate The Clinical Development Of Lbps Pipelines

Jul 07, 2022•about 3 years ago

Amount Raised

$45 Million

Round Type

series b

Guangzhou

Description

Recently, Zhiyi Biotech announced that it has raised $15 million in its B++ funding round. The funds will be used to boost the clinical development of the company's live biotherapeutic products (LBPs) pipelines. It's worth mentioning that Zhiyi has successfully completed a total of $45 Million in B, B+ and B++ funding , with investors including Qingkong SinoKing Capital, SDIC Venture Capital, KIP etc.

Company Information

Company

Zhiyi Biotech

Location

Guangzhou, Guangdong Province, China

About

Zhiyi Biotech, founded in 2013, is located in Guangzhou, China. Its lead candidate SK08 is not only the first new strain-based LBP that entered clinical stage in China, but also the first LBP in oncology that was approved for clinical trial by NMPA. Owning two commercial-scale facilities, Zhiyi has established a complete platform system for strain selection, druggability study, CMC study, commercial production etc. For more information, please visit https://www.zypharm.com.cn or contact public@zypharm.com.cn SOURCE Zhiyi Biotech

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data

Tech investment trends